This document provides an overview of targeted chemotherapy and reviews recent developments. It discusses how targeted therapies like monoclonal antibodies and small molecule inhibitors precisely target molecular changes in cancer cells, potentially causing fewer side effects than traditional chemotherapy. The document outlines several FDA-approved targeted drugs and their indications. It also discusses considerations for targeted therapy like evaluating effectiveness through biomarkers, increased costs compared to chemotherapy, and challenges in determining optimal dosing. Future areas of research discussed include personalized treatment based on a patient's molecular profile and defining dose-response relationships through randomized trials.
This document discusses new strategies for combating cancer through molecular biology approaches. It describes prevention strategies that focus on pre-invasive lesions by inhibiting carcinogen initiation events, cell proliferation associated with promotion, or the development of the invasive phenotype in precancerous lesions. Targets for prevention strategies include biochemical species produced by carcinogens and aberrantly expressed proteins from genetic/environmental risk factors. Gene expression profiling using cDNA microarrays can help understand carcinogenesis at the molecular level and identify new therapeutic targets. The document also discusses inhibiting metastasis through strategies like modifying cell adhesion with MMP inhibitors or anticoagulants, and inhibiting angiogenesis. Gene therapy approaches for cancer treatment aim to correct genetic mutations or deliver therapeutic genes to stimulate anti-tumor immune
Sodium butyrate, a histone deacetylase inhibitor, was shown to decrease expression of the MDR1 gene in PC3 prostate cancer cells. MDR1 encodes an efflux transporter protein that is responsible for chemotherapy resistance. Histone deacetylase inhibitors have potential as prostate cancer therapeutics by inducing cell growth arrest, differentiation and apoptosis. Further studies aim to elucidate the mechanism by which sodium butyrate downregulates MDR1 expression and how this affects chemotherapy resistance.
The document discusses the principles of chemoradiation therapy. It describes how combining chemotherapy and radiation therapy can improve outcomes for cancer patients by enhancing local tumor control and reducing metastases. Several key studies from the 1950s-1970s helped establish chemoradiation as an effective approach. The combination of therapies aims to increase the therapeutic index by exploiting differences between tumor and normal tissues at the biological level. Strategies include achieving spatial cooperation between treatments, independent toxicity profiles, enhanced tumor response, and protection of normal tissues. A variety of chemotherapy agents can be used as radiosensitizers or radioprotectors when combined judiciously with radiation based on their mechanisms of action and side effect profiles.
1. Several Pancratistatin (PST) analogs, including SVTH-7, SVTH-6, and SVTH-5, were found to have potent anti-cancer activity greater than PST and standard chemotherapeutics in a medium-throughput screen of various cancer cell lines.
2. The PST analogs disrupted mitochondrial function, activated the intrinsic apoptotic pathway, and reduced tumor growth in vivo. Inhibition of mitochondrial complexes II and III abrogated the pro-apoptotic effects of SVTH-7, suggesting it exploits a mitochondrial vulnerability.
3. This work identifies several PST analogs with high therapeutic potential and provides insight into distinct mitochondrial features of cancer
This document discusses chemoprevention for cancer. It defines chemoprevention as using chemicals to interfere with cell division processes so cancer cells commit suicide. Chemoprevention is divided into primary, secondary, and tertiary prevention based on risk levels. The ideal chemopreventive agent is inexpensive, safe, and effective with minimal side effects for long-term use. The document then discusses how chemoprevention works on tumor cells and by histone modifications. It describes epigenetic therapy and drugs used for this therapy. Finally, it discusses how phytochemicals from plants like green tea, curcumin, caffeine, and gingerol can also help prevent cancer.
Peptidomimetics are being researched as potential anti-cancer drugs with increased selectivity for cancer cells and reduced toxicity compared to existing drugs like cisplatin. Peptidomimetics are thought to induce apoptosis in cancer cells by crosslinking with DNA in the major groove, altering DNA structure and increasing the population of cells in the G1 stage of mitosis. One peptidomimetic drug candidate, AuD8, inhibits tumor growth in mice by binding to proteasomes and inhibiting protein degradation, leading to accumulation of ubiquitin proteins and apoptosis. Triplex metallohelices show potential as well through selective cytotoxicity against various cancer cell lines. However, more research is needed to improve production methods and translate
1. Aberrations in sphingolipid metabolism are implicated in promoting glioblastoma multiforme (GBM) aggressiveness. GBM exhibits lower levels of ceramide and higher levels of sphingosine-1-phosphate (S1P) compared to normal brain tissue.
2. GBM manipulates sphingolipid pathways to shift the balance towards higher S1P and lower ceramide. Mechanisms include upregulating S1P-producing enzymes and downregulating ceramide-producing enzymes and phosphatases.
3. Receptors for the bioactive sphingolipid S1P are also upregulated in GBM, suggesting S1P signaling contributes to GBM
This document summarizes recent advances in immunotherapy for solid tumors. It discusses how immunotherapy has established itself as an effective treatment strategy, building on William Coley's pioneering work in the late 1800s using bacteria to elicit anti-tumor immune responses. The document outlines several key immunotherapy approaches, including immune checkpoint inhibitors, adoptive cellular therapy, strategies to enhance tumor immunogenicity like radiotherapy and oncolytic viruses, and cancer vaccines. It also discusses how tumor-infiltrating lymphocytes and immunoscore can help predict cancer prognosis and how the immune system interacts with tumors.
This document discusses new strategies for combating cancer through molecular biology approaches. It describes prevention strategies that focus on pre-invasive lesions by inhibiting carcinogen initiation events, cell proliferation associated with promotion, or the development of the invasive phenotype in precancerous lesions. Targets for prevention strategies include biochemical species produced by carcinogens and aberrantly expressed proteins from genetic/environmental risk factors. Gene expression profiling using cDNA microarrays can help understand carcinogenesis at the molecular level and identify new therapeutic targets. The document also discusses inhibiting metastasis through strategies like modifying cell adhesion with MMP inhibitors or anticoagulants, and inhibiting angiogenesis. Gene therapy approaches for cancer treatment aim to correct genetic mutations or deliver therapeutic genes to stimulate anti-tumor immune
Sodium butyrate, a histone deacetylase inhibitor, was shown to decrease expression of the MDR1 gene in PC3 prostate cancer cells. MDR1 encodes an efflux transporter protein that is responsible for chemotherapy resistance. Histone deacetylase inhibitors have potential as prostate cancer therapeutics by inducing cell growth arrest, differentiation and apoptosis. Further studies aim to elucidate the mechanism by which sodium butyrate downregulates MDR1 expression and how this affects chemotherapy resistance.
The document discusses the principles of chemoradiation therapy. It describes how combining chemotherapy and radiation therapy can improve outcomes for cancer patients by enhancing local tumor control and reducing metastases. Several key studies from the 1950s-1970s helped establish chemoradiation as an effective approach. The combination of therapies aims to increase the therapeutic index by exploiting differences between tumor and normal tissues at the biological level. Strategies include achieving spatial cooperation between treatments, independent toxicity profiles, enhanced tumor response, and protection of normal tissues. A variety of chemotherapy agents can be used as radiosensitizers or radioprotectors when combined judiciously with radiation based on their mechanisms of action and side effect profiles.
1. Several Pancratistatin (PST) analogs, including SVTH-7, SVTH-6, and SVTH-5, were found to have potent anti-cancer activity greater than PST and standard chemotherapeutics in a medium-throughput screen of various cancer cell lines.
2. The PST analogs disrupted mitochondrial function, activated the intrinsic apoptotic pathway, and reduced tumor growth in vivo. Inhibition of mitochondrial complexes II and III abrogated the pro-apoptotic effects of SVTH-7, suggesting it exploits a mitochondrial vulnerability.
3. This work identifies several PST analogs with high therapeutic potential and provides insight into distinct mitochondrial features of cancer
This document discusses chemoprevention for cancer. It defines chemoprevention as using chemicals to interfere with cell division processes so cancer cells commit suicide. Chemoprevention is divided into primary, secondary, and tertiary prevention based on risk levels. The ideal chemopreventive agent is inexpensive, safe, and effective with minimal side effects for long-term use. The document then discusses how chemoprevention works on tumor cells and by histone modifications. It describes epigenetic therapy and drugs used for this therapy. Finally, it discusses how phytochemicals from plants like green tea, curcumin, caffeine, and gingerol can also help prevent cancer.
Peptidomimetics are being researched as potential anti-cancer drugs with increased selectivity for cancer cells and reduced toxicity compared to existing drugs like cisplatin. Peptidomimetics are thought to induce apoptosis in cancer cells by crosslinking with DNA in the major groove, altering DNA structure and increasing the population of cells in the G1 stage of mitosis. One peptidomimetic drug candidate, AuD8, inhibits tumor growth in mice by binding to proteasomes and inhibiting protein degradation, leading to accumulation of ubiquitin proteins and apoptosis. Triplex metallohelices show potential as well through selective cytotoxicity against various cancer cell lines. However, more research is needed to improve production methods and translate
1. Aberrations in sphingolipid metabolism are implicated in promoting glioblastoma multiforme (GBM) aggressiveness. GBM exhibits lower levels of ceramide and higher levels of sphingosine-1-phosphate (S1P) compared to normal brain tissue.
2. GBM manipulates sphingolipid pathways to shift the balance towards higher S1P and lower ceramide. Mechanisms include upregulating S1P-producing enzymes and downregulating ceramide-producing enzymes and phosphatases.
3. Receptors for the bioactive sphingolipid S1P are also upregulated in GBM, suggesting S1P signaling contributes to GBM
This document summarizes recent advances in immunotherapy for solid tumors. It discusses how immunotherapy has established itself as an effective treatment strategy, building on William Coley's pioneering work in the late 1800s using bacteria to elicit anti-tumor immune responses. The document outlines several key immunotherapy approaches, including immune checkpoint inhibitors, adoptive cellular therapy, strategies to enhance tumor immunogenicity like radiotherapy and oncolytic viruses, and cancer vaccines. It also discusses how tumor-infiltrating lymphocytes and immunoscore can help predict cancer prognosis and how the immune system interacts with tumors.
Chemotherapeutic enzymes target the nucleotide biosynthetic pathway by inhibiting enzymes involved in DNA and RNA synthesis. Nucleotides are essential for cell survival and proliferation, and tumor cells have high concentrations of nucleotide metabolites. Chemotherapeutic drugs work by blocking DNA synthesis, causing lethal events in rapidly dividing cancer cells and arresting tumor progression. Specifically, antimetabolites like methotrexate and 6-mercaptopurine interfere with folate and purine metabolism, halting cancer cell division. By targeting nucleotide biosynthesis, chemotherapy aims to stop uncontrolled tumor cell growth.
This document discusses targeted cancer therapies, which work by interfering with specific molecular targets involved in cancer growth and progression, unlike traditional chemotherapy which acts on all rapidly dividing cells. It provides examples of molecular targets for small molecule drugs and monoclonal antibodies, including growth factor receptors and fusion proteins. The document also discusses methods of target identification, categories of targeted therapies, examples of FDA-approved targeted drugs, limitations and side effects of targeted therapies, and concludes by emphasizing the importance and promise of targeted therapies while noting challenges that remain.
This document discusses biomarkers and their emerging applications in healthcare. It defines biomarkers as small protein or peptide molecules involved in cell signaling and gene regulation. Biomarkers can be used to detect different cancer stages, identify cancer types, and guide cancer therapy. The document outlines several applications of biomarkers, including disease screening, drug development, and understanding molecular changes in diseases. It provides examples of biomarkers used for cancers like ovarian, prostate, liver, and breast cancer. The document also discusses techniques used to analyze biomarkers, such as mass spectrometry, and how biomarkers can help study conditions like Alzheimer's and Parkinson's disease.
This document discusses doxorubicin (Dox), a commonly used chemotherapeutic agent, and its ability to induce autophagy in tumor cells and cardiomyocytes. Recent research has identified several major biomarkers, such as AMPK, p53, and Bcl-2, that are important for Dox-induced apoptosis. In particular, it is Bcl-2's interaction with Beclin-1 that has refocused attention on Dox's ability to induce autophagy. The document suggests that further research into Dox's molecular signaling in neoplastic and normal cells may help redefine how Dox is clinically used and lead to improved cancer management by potentially exploiting autophagy.
Nanoparticle (NP) Delivery of Chemotherapy
Drugs to Prostate Cancer Patients by Toluleke Oloruntobi Famuyiwa* and James Kwasi Kumi-Diaka in Integrative Journal of Conference Proceedings
Herbal and Synthetic Drug Combinations in Cancer Therapy A Reviewijtsrd
Cancer is one of the leading and most serious diseases in the current decade, every year millions of people die because of various kinds of cancers. Many aspects relate to the cause of disease besides heredity, food habits, smoking, nutritional behaviors, radiation etc. Cancer is a high mortality disease and the therapeutics for cancer, especially for cancer metastasis is still imperfect. The successful cancer treatment till now has been under study, only chemotherapy and radiation treatments are at times successful. Alternative and less toxic medication is very much in need towards the disease, the use of concepts of herbal medicine with synthetic drug could present better drug leads towards the inhibitory treatment of Cancer. Nature shows plethora of medicinal plants with anticancer and antioxidant activities which may suppress the disease completely. By applying combination therapy instead of monotherapy can lead to improved efficacy and reduced toxicity of the conventional method of treatments of cancer. Anusree S | Dr. Silvia Navis A | Dr. Prashob G R "Herbal and Synthetic Drug Combinations in Cancer Therapy- A Review" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5 , August 2019, URL: https://www.ijtsrd.com/papers/ijtsrd25222.pdfPaper URL: https://www.ijtsrd.com/pharmacy/pharmacology-/25222/herbal-and-synthetic-drug-combinations-in-cancer-therapy--a-review/anusree-s
Advances in cell biology: contribution to drug modern designEsayas Ayele
This document discusses how advances in cell biology have contributed to modern drug design. It outlines how understanding cell structures and functions through areas like proteomics, genomics, and studies of proteins, membranes, and nucleic acids has provided insights for identifying new drug targets. Characterizing proteins of interest like G protein-coupled receptors and enzymes has allowed designing drugs that interact with specific targets linked to various diseases.
This document summarizes a study evaluating the toxicity and efficacy of novel targeted polymalic acid conjugate nanoparticles for treating triple-negative breast cancer. The nanoparticles were designed to target the epidermal growth factor receptor and laminin-411, a tumor vascular protein. In vitro and in vivo assays were conducted to evaluate the biocompatibility and toxicity of the polymalic acid platform and nanoparticle conjugates at low and high doses, as well as their efficacy in reducing tumor growth in mouse models over multiple treatment regimens. Blood analysis after intravenous administration in mice found no side effects, supporting the safety and potential of these nanoparticles for future cancer treatment in patients.
This document discusses genetic polymorphisms in drug transport proteins and how they can impact drug pharmacokinetics and toxicity. It introduces two major superfamilies of transport proteins - ATP-binding cassette (ABC) transporters and solute carrier (SLC) proteins. Specific ABC transporters discussed include P-glycoprotein (ABCB1), the multidrug resistance proteins ABCC1 and ABCG2. The document also summarizes key SLC transporters and provides examples of important substrates for each. Genetic variations in these transport proteins can significantly influence individual responses to drugs like irinotecan used in cancer chemotherapy.
This document summarizes a study examining EphB4 as a potential therapeutic target in mesothelioma. The study found that EphB4 is overexpressed in 72% of human mesothelioma tissue samples, particularly in epithelioid subtypes. Treatment with an EphB4 inhibitor called sEphB4-HSA significantly inhibited tumor growth in mesothelioma xenograft models by inducing apoptosis and inhibiting PI3K and Src signaling. Combination treatment with sEphB4-HSA and an anti-VEGF antibody was more effective than either treatment alone and led to complete tumor regression in some cases. These results suggest that targeting EphB4, particularly with s
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
The document discusses pharmacogenomics and how genetic variations can affect individual responses to drugs. It describes how pharmacogenomics examines genomic loci and biological pathways to determine drug variability. It also discusses pharmacogenetics which focuses on single gene variants. The document outlines some merits of pharmacogenomics like improving drug safety and personalized treatment. It then discusses various scenarios on how genetic polymorphisms can impact different drug metabolism pathways. Finally, it examines how specific genetic variations in drug metabolizing enzymes and transporters can influence drug pharmacokinetics and potential adverse effects.
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014Työterveyslaitos
1. Asbestos fibers cause chronic inflammation in the lungs and pleura, which enables the development of cancers through tumor-promoting inflammation and genomic instability from oxidative DNA damage.
2. The tumor microenvironment in asbestos-related cancers is immunosuppressive, allowing tumors to evade immune destruction.
3. Targeting chronic inflammation and harnessing the host immune response, in addition to cytotoxic therapies, may be more effective against asbestos-related cancers than cytotoxic agents alone.
This research paper examines the ability of the drug nelfinavir to overcome multidrug resistance in MCF-7/Dox breast cancer cells. The study finds that multiple exposures to physiologically achievable concentrations of nelfinavir can significantly decrease the doxorubicin IC50 in MCF-7/Dox cells by inhibiting P-glycoprotein expression and function, suppressing AKT signaling pathways, and inducing endoplasmic reticulum stress pathways. In mouse models carrying MCF-7/Dox tumor xenografts, combination treatment with nelfinavir and doxorubicin decreased tumor growth more than either drug alone. The results suggest that nelfinavir can overcome multiple drug resistance
This document discusses pharmacogenomics and how genetic differences can influence individual responses to drugs. It provides examples of how single nucleotide polymorphisms and other genetic variations can affect drug targets, metabolizing enzymes, transporters, and ultimately impact pharmacokinetics, pharmacodynamics, efficacy, and toxicity. Specifically, it examines cases of polymorphisms in cytochrome P450 drug metabolizing enzymes like CYP2C9, CYP2C19, and CYP2D6 that can lead to differences in drug metabolism and clearance between fast, normal, and poor metabolizers. The goals of pharmacogenomics are to maximize drug efficacy, minimize toxicity, and aid precision medicine by predicting who will respond to certain drugs. Widespread application
Polymorphism affecting drug metabolismDeepak Kumar
Genetic polymorphisms can affect how individuals metabolize and respond to drugs. Variations in genes encoding drug-metabolizing enzymes like CYP450 isoforms can result in poor, intermediate, extensive, or ultra-rapid metabolizer phenotypes. This impacts how effectively an individual metabolizes and eliminates drugs from the body. The effects of inhibitors and inducers on drug metabolism also differ depending on a person's metabolizer phenotype. Understanding these genetic factors is important for predicting drug responses and interactions between a drug and other substances in an individual.
Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple P...AB SCIEX India
Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple Protease Digestion with Data-Dependent (MS1) and Data-Independent (MS2) Acquisitions :
Mass spectrometry-based proteomics combined with
stable-isotope labeling or tagging is a powerful technique for large-scale quantitation and unbiased characterization of the proteome. Nonetheless, it is well known that unbiased discovery proteomics typically suffers from limited dynamic range and sampling efficiency, which can only be partially addressed by incorporating orthogonal fractionation steps.
Influence of a six month endurance exercise program on the immune function of...Enrique Moreno Gonzalez
Exercise seems to minimize prostate cancer specific mortality risk and treatment related side effects like fatigue and incontinence. However the influence of physical activity on the immunological level remains uncertain. Even prostate cancer patients undergoing palliative treatment often have a relatively long life span compared to other cancer entities. To optimize exercise programs and their outcomes it is essential to investigate the underlying mechanisms. Further, it is important to discriminate between different exercise protocols and therapy regimes.
Immunotherapeutic drugs can be broadly classified into four types: checkpoint inhibitors, cytokines, monoclonal antibodies, and vaccines. However, immunotherapeutic drugs still have some problems, such as off-target side effects and poor pharmacokinetics.
The use of genetic engineering technology in animals has been associated with ethical issues, some of which relate to animal welfare. Discuss examples of genetically engineering animals and evaluate the ethical concerns of genetic engineering.
Conquering Difficulties of Immunotherapy in Forceful Blood Disease--.pdfsyedanusrat1234
In tending to the intricacies of serious blood disease cure, the blending of corresponding pharmacotherapy has arisen as a vital procedure. This far-reaching technique offers a promising answer for overcoming the difficulties connected with immunotherapy in most malignant blood growth.
A multidisciplinary strategy is necessary to overcome the obstacles associated with immunotherapy in aggressive blood disorders. It is crucial to emphasize in presentations the complexity of the immune system's interactions with cancer cells, including evasion strategies and immune suppression occurring inside the tumor micro-environment. It can give hope to highlight the continuous research being done to clarify these pathways and create novel immunotherapy approaches specific to blood malignancies.
The possibility for overcoming resistance and improving treatment results might be emphasized by talking about the significance of combination medicines, biomarker identification, and patient stratification based on molecular profiling. Furthermore, highlighting the improvements in survival rates and quality of life that immunotherapy has brought about for patients with severe blood illnesses can inspire additional funding and cooperation in this vital field of cancer research and care.
Figuring out the Scene of Forceful Blood Malignant growth
Forceful blood malignant growths, which incorporate intense myeloid leukemia (AML) and high-risk myelodysplastic disorders (MDS), present strong constraints in ideal therapy models. These malignancies are described via expedient turn of events and protection from ordinary cures, requiring inventive techniques for strong administration.
Determining the site of a potent blood danger necessitates a complex analysis of various factors, such as genetic alterations, environmental effects, and adaptive system responses. Researchers study how these elements work together to drive the development of aggressive blood cancers such as lymphoma and leukemia. Through deciphering the fundamental mechanisms underlying these illnesses, scientists hope to develop targeted therapies that disrupt carcinogenic cycles while confining damage to healthy cells.
Developments in personalized medicine and genomic profiling present intriguing avenues for tailoring drugs to specific patients, improving outcomes, and raising overall endurance rates. Furthermore, ongoing efforts to unravel the complexities of growth micro-environments provide important insights into potential therapeutic targets and systems to effectively combat aggressive blood cancers.
1) The document discusses various mechanisms of cancer drug resistance, including decreased drug accumulation, alterations in drug targets, drug efflux, compartmentalization, altered apoptosis and autophagy pathways, and the role of the tumor microenvironment in providing protection.
2) It also reviews ways to potentially overcome resistance, such as through multidrug resistance modulators, targeted therapies, immunotherapy and combination therapies.
3) However, it notes that cancer progression, metastasis, inherited or acquired drug resistance, and incomplete understanding of resistance mechanisms still pose challenges to effective cancer treatment.
Chemotherapeutic enzymes target the nucleotide biosynthetic pathway by inhibiting enzymes involved in DNA and RNA synthesis. Nucleotides are essential for cell survival and proliferation, and tumor cells have high concentrations of nucleotide metabolites. Chemotherapeutic drugs work by blocking DNA synthesis, causing lethal events in rapidly dividing cancer cells and arresting tumor progression. Specifically, antimetabolites like methotrexate and 6-mercaptopurine interfere with folate and purine metabolism, halting cancer cell division. By targeting nucleotide biosynthesis, chemotherapy aims to stop uncontrolled tumor cell growth.
This document discusses targeted cancer therapies, which work by interfering with specific molecular targets involved in cancer growth and progression, unlike traditional chemotherapy which acts on all rapidly dividing cells. It provides examples of molecular targets for small molecule drugs and monoclonal antibodies, including growth factor receptors and fusion proteins. The document also discusses methods of target identification, categories of targeted therapies, examples of FDA-approved targeted drugs, limitations and side effects of targeted therapies, and concludes by emphasizing the importance and promise of targeted therapies while noting challenges that remain.
This document discusses biomarkers and their emerging applications in healthcare. It defines biomarkers as small protein or peptide molecules involved in cell signaling and gene regulation. Biomarkers can be used to detect different cancer stages, identify cancer types, and guide cancer therapy. The document outlines several applications of biomarkers, including disease screening, drug development, and understanding molecular changes in diseases. It provides examples of biomarkers used for cancers like ovarian, prostate, liver, and breast cancer. The document also discusses techniques used to analyze biomarkers, such as mass spectrometry, and how biomarkers can help study conditions like Alzheimer's and Parkinson's disease.
This document discusses doxorubicin (Dox), a commonly used chemotherapeutic agent, and its ability to induce autophagy in tumor cells and cardiomyocytes. Recent research has identified several major biomarkers, such as AMPK, p53, and Bcl-2, that are important for Dox-induced apoptosis. In particular, it is Bcl-2's interaction with Beclin-1 that has refocused attention on Dox's ability to induce autophagy. The document suggests that further research into Dox's molecular signaling in neoplastic and normal cells may help redefine how Dox is clinically used and lead to improved cancer management by potentially exploiting autophagy.
Nanoparticle (NP) Delivery of Chemotherapy
Drugs to Prostate Cancer Patients by Toluleke Oloruntobi Famuyiwa* and James Kwasi Kumi-Diaka in Integrative Journal of Conference Proceedings
Herbal and Synthetic Drug Combinations in Cancer Therapy A Reviewijtsrd
Cancer is one of the leading and most serious diseases in the current decade, every year millions of people die because of various kinds of cancers. Many aspects relate to the cause of disease besides heredity, food habits, smoking, nutritional behaviors, radiation etc. Cancer is a high mortality disease and the therapeutics for cancer, especially for cancer metastasis is still imperfect. The successful cancer treatment till now has been under study, only chemotherapy and radiation treatments are at times successful. Alternative and less toxic medication is very much in need towards the disease, the use of concepts of herbal medicine with synthetic drug could present better drug leads towards the inhibitory treatment of Cancer. Nature shows plethora of medicinal plants with anticancer and antioxidant activities which may suppress the disease completely. By applying combination therapy instead of monotherapy can lead to improved efficacy and reduced toxicity of the conventional method of treatments of cancer. Anusree S | Dr. Silvia Navis A | Dr. Prashob G R "Herbal and Synthetic Drug Combinations in Cancer Therapy- A Review" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5 , August 2019, URL: https://www.ijtsrd.com/papers/ijtsrd25222.pdfPaper URL: https://www.ijtsrd.com/pharmacy/pharmacology-/25222/herbal-and-synthetic-drug-combinations-in-cancer-therapy--a-review/anusree-s
Advances in cell biology: contribution to drug modern designEsayas Ayele
This document discusses how advances in cell biology have contributed to modern drug design. It outlines how understanding cell structures and functions through areas like proteomics, genomics, and studies of proteins, membranes, and nucleic acids has provided insights for identifying new drug targets. Characterizing proteins of interest like G protein-coupled receptors and enzymes has allowed designing drugs that interact with specific targets linked to various diseases.
This document summarizes a study evaluating the toxicity and efficacy of novel targeted polymalic acid conjugate nanoparticles for treating triple-negative breast cancer. The nanoparticles were designed to target the epidermal growth factor receptor and laminin-411, a tumor vascular protein. In vitro and in vivo assays were conducted to evaluate the biocompatibility and toxicity of the polymalic acid platform and nanoparticle conjugates at low and high doses, as well as their efficacy in reducing tumor growth in mouse models over multiple treatment regimens. Blood analysis after intravenous administration in mice found no side effects, supporting the safety and potential of these nanoparticles for future cancer treatment in patients.
This document discusses genetic polymorphisms in drug transport proteins and how they can impact drug pharmacokinetics and toxicity. It introduces two major superfamilies of transport proteins - ATP-binding cassette (ABC) transporters and solute carrier (SLC) proteins. Specific ABC transporters discussed include P-glycoprotein (ABCB1), the multidrug resistance proteins ABCC1 and ABCG2. The document also summarizes key SLC transporters and provides examples of important substrates for each. Genetic variations in these transport proteins can significantly influence individual responses to drugs like irinotecan used in cancer chemotherapy.
This document summarizes a study examining EphB4 as a potential therapeutic target in mesothelioma. The study found that EphB4 is overexpressed in 72% of human mesothelioma tissue samples, particularly in epithelioid subtypes. Treatment with an EphB4 inhibitor called sEphB4-HSA significantly inhibited tumor growth in mesothelioma xenograft models by inducing apoptosis and inhibiting PI3K and Src signaling. Combination treatment with sEphB4-HSA and an anti-VEGF antibody was more effective than either treatment alone and led to complete tumor regression in some cases. These results suggest that targeting EphB4, particularly with s
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
The document discusses pharmacogenomics and how genetic variations can affect individual responses to drugs. It describes how pharmacogenomics examines genomic loci and biological pathways to determine drug variability. It also discusses pharmacogenetics which focuses on single gene variants. The document outlines some merits of pharmacogenomics like improving drug safety and personalized treatment. It then discusses various scenarios on how genetic polymorphisms can impact different drug metabolism pathways. Finally, it examines how specific genetic variations in drug metabolizing enzymes and transporters can influence drug pharmacokinetics and potential adverse effects.
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014Työterveyslaitos
1. Asbestos fibers cause chronic inflammation in the lungs and pleura, which enables the development of cancers through tumor-promoting inflammation and genomic instability from oxidative DNA damage.
2. The tumor microenvironment in asbestos-related cancers is immunosuppressive, allowing tumors to evade immune destruction.
3. Targeting chronic inflammation and harnessing the host immune response, in addition to cytotoxic therapies, may be more effective against asbestos-related cancers than cytotoxic agents alone.
This research paper examines the ability of the drug nelfinavir to overcome multidrug resistance in MCF-7/Dox breast cancer cells. The study finds that multiple exposures to physiologically achievable concentrations of nelfinavir can significantly decrease the doxorubicin IC50 in MCF-7/Dox cells by inhibiting P-glycoprotein expression and function, suppressing AKT signaling pathways, and inducing endoplasmic reticulum stress pathways. In mouse models carrying MCF-7/Dox tumor xenografts, combination treatment with nelfinavir and doxorubicin decreased tumor growth more than either drug alone. The results suggest that nelfinavir can overcome multiple drug resistance
This document discusses pharmacogenomics and how genetic differences can influence individual responses to drugs. It provides examples of how single nucleotide polymorphisms and other genetic variations can affect drug targets, metabolizing enzymes, transporters, and ultimately impact pharmacokinetics, pharmacodynamics, efficacy, and toxicity. Specifically, it examines cases of polymorphisms in cytochrome P450 drug metabolizing enzymes like CYP2C9, CYP2C19, and CYP2D6 that can lead to differences in drug metabolism and clearance between fast, normal, and poor metabolizers. The goals of pharmacogenomics are to maximize drug efficacy, minimize toxicity, and aid precision medicine by predicting who will respond to certain drugs. Widespread application
Polymorphism affecting drug metabolismDeepak Kumar
Genetic polymorphisms can affect how individuals metabolize and respond to drugs. Variations in genes encoding drug-metabolizing enzymes like CYP450 isoforms can result in poor, intermediate, extensive, or ultra-rapid metabolizer phenotypes. This impacts how effectively an individual metabolizes and eliminates drugs from the body. The effects of inhibitors and inducers on drug metabolism also differ depending on a person's metabolizer phenotype. Understanding these genetic factors is important for predicting drug responses and interactions between a drug and other substances in an individual.
Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple P...AB SCIEX India
Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple Protease Digestion with Data-Dependent (MS1) and Data-Independent (MS2) Acquisitions :
Mass spectrometry-based proteomics combined with
stable-isotope labeling or tagging is a powerful technique for large-scale quantitation and unbiased characterization of the proteome. Nonetheless, it is well known that unbiased discovery proteomics typically suffers from limited dynamic range and sampling efficiency, which can only be partially addressed by incorporating orthogonal fractionation steps.
Influence of a six month endurance exercise program on the immune function of...Enrique Moreno Gonzalez
Exercise seems to minimize prostate cancer specific mortality risk and treatment related side effects like fatigue and incontinence. However the influence of physical activity on the immunological level remains uncertain. Even prostate cancer patients undergoing palliative treatment often have a relatively long life span compared to other cancer entities. To optimize exercise programs and their outcomes it is essential to investigate the underlying mechanisms. Further, it is important to discriminate between different exercise protocols and therapy regimes.
Immunotherapeutic drugs can be broadly classified into four types: checkpoint inhibitors, cytokines, monoclonal antibodies, and vaccines. However, immunotherapeutic drugs still have some problems, such as off-target side effects and poor pharmacokinetics.
The use of genetic engineering technology in animals has been associated with ethical issues, some of which relate to animal welfare. Discuss examples of genetically engineering animals and evaluate the ethical concerns of genetic engineering.
Conquering Difficulties of Immunotherapy in Forceful Blood Disease--.pdfsyedanusrat1234
In tending to the intricacies of serious blood disease cure, the blending of corresponding pharmacotherapy has arisen as a vital procedure. This far-reaching technique offers a promising answer for overcoming the difficulties connected with immunotherapy in most malignant blood growth.
A multidisciplinary strategy is necessary to overcome the obstacles associated with immunotherapy in aggressive blood disorders. It is crucial to emphasize in presentations the complexity of the immune system's interactions with cancer cells, including evasion strategies and immune suppression occurring inside the tumor micro-environment. It can give hope to highlight the continuous research being done to clarify these pathways and create novel immunotherapy approaches specific to blood malignancies.
The possibility for overcoming resistance and improving treatment results might be emphasized by talking about the significance of combination medicines, biomarker identification, and patient stratification based on molecular profiling. Furthermore, highlighting the improvements in survival rates and quality of life that immunotherapy has brought about for patients with severe blood illnesses can inspire additional funding and cooperation in this vital field of cancer research and care.
Figuring out the Scene of Forceful Blood Malignant growth
Forceful blood malignant growths, which incorporate intense myeloid leukemia (AML) and high-risk myelodysplastic disorders (MDS), present strong constraints in ideal therapy models. These malignancies are described via expedient turn of events and protection from ordinary cures, requiring inventive techniques for strong administration.
Determining the site of a potent blood danger necessitates a complex analysis of various factors, such as genetic alterations, environmental effects, and adaptive system responses. Researchers study how these elements work together to drive the development of aggressive blood cancers such as lymphoma and leukemia. Through deciphering the fundamental mechanisms underlying these illnesses, scientists hope to develop targeted therapies that disrupt carcinogenic cycles while confining damage to healthy cells.
Developments in personalized medicine and genomic profiling present intriguing avenues for tailoring drugs to specific patients, improving outcomes, and raising overall endurance rates. Furthermore, ongoing efforts to unravel the complexities of growth micro-environments provide important insights into potential therapeutic targets and systems to effectively combat aggressive blood cancers.
1) The document discusses various mechanisms of cancer drug resistance, including decreased drug accumulation, alterations in drug targets, drug efflux, compartmentalization, altered apoptosis and autophagy pathways, and the role of the tumor microenvironment in providing protection.
2) It also reviews ways to potentially overcome resistance, such as through multidrug resistance modulators, targeted therapies, immunotherapy and combination therapies.
3) However, it notes that cancer progression, metastasis, inherited or acquired drug resistance, and incomplete understanding of resistance mechanisms still pose challenges to effective cancer treatment.
This white paper discusses improving the clinical development of cancer immunotherapies. It outlines the current immunotherapy landscape including checkpoint inhibitors, adoptive T cell therapies, cancer vaccines, and biomarkers. The paper emphasizes that while immunotherapy has promising results for some patients and cancer types, more research is needed to understand which patients will benefit most from which approaches and how to best leverage various immune system components in the fight against cancer. Operational considerations and cautions for clinical development are also discussed.
The document discusses targeted therapy and its role in treating cancer. It defines targeted therapy as using drugs or substances to recognize and kill cancer cells without harming normal cells. It provides examples of targeted therapy drugs, including Gleevec/Imatinib which treats chronic myeloid leukemia, Velcade/Bortezomib which treats multiple myelomas, and Sutent which treats kidney cancer. The document also discusses how these drugs work, such as by inhibiting tyrosine kinases or blocking protein breakdown in cancer cells.
This document discusses the clinical development of monoclonal antibody therapies for cancer treatment. It focuses on five FDA-approved antibodies - rituximab, trastuzumab, bevacizumab, cetuximab, and panitumumab. The document summarizes the clinical trials that led to the approval of rituximab for treating lymphoma, including early phase trials showing efficacy as a single agent and a pivotal trial demonstrating an overall response rate of 48%. It also discusses the mechanisms of action of antibody cancer therapies and opportunities and challenges for developing such therapies in China.
This document discusses tumor cell proliferation and immunotherapy for cancers. It provides details on the cell cycle phases (M, G1, S, G2, G0) and how they relate to tumor growth and response to treatment. It also discusses cell kinetics, the growth fraction, and cancer stem cells. Targeted therapies discussed include those that inhibit angiogenesis by targeting VEGF, as well as EGFR inhibitors. Bevacizumab is highlighted as an anti-angiogenic therapy shown to improve outcomes for ovarian cancer both as a single agent and in combination with other drugs.
Siva Bharathi.U I MSc Microbiology SPKC (1).pptxSivaBharathi20
Title: Applications of Monoclonal Antibodies
Introduction:
Monoclonal antibodies (mAbs) are highly specific molecules that can bind to a single antigen or epitope. They have a wide range of applications in medicine, research, and industry. In this presentation, we will explore some of the key applications of monoclonal antibodies and their potential impact on various fields.
Section 1: Therapeutic Applications
Monoclonal antibodies have revolutionized the field of immunotherapy, providing targeted treatments for a range of diseases, including cancer, autoimmune disorders, and infectious diseases.
We will discuss some examples of FDA-approved monoclonal antibody therapies and their mechanism of action.
We will also touch on some of the challenges and limitations of using monoclonal antibodies as therapeutics.
Section 2: Diagnostic Applications
Monoclonal antibodies are widely used in diagnostic assays to detect and measure specific biomolecules.
We will look at some common diagnostic applications of monoclonal antibodies, including ELISA, Western blotting, and flow cytometry.
We will also discuss the advantages and limitations of using monoclonal antibodies in diagnostic assays.
Section 3: Research Applications
Monoclonal antibodies have become essential tools in biomedical research, allowing scientists to selectively target and manipulate specific cells or molecules.
We will explore some of the research applications of monoclonal antibodies, including their use in studying protein function, cell signaling, and disease mechanisms.
We will also discuss some of the emerging research areas where monoclonal antibodies are being explored as potential therapies, such as neurodegenerative diseases and regenerative medicine.
Conclusion:
Monoclonal antibodies have transformed the way we approach disease diagnosis, treatment, and research. Their high specificity, versatility, and selectivity make them valuable tools for a range of applications. As research continues to advance, we can expect to see even more exciting applications of monoclonal antibodies in the future.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...JohnJulie1
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...daranisaha
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients. Drug repurposing sometimes-termed drug repositioning is a strategy of discovery and redeveloping existing drugs for new therapeutic purposes. This novel approach is highly efficient, considerably cuts research and development costs, reduces the drug development timeline, maximizes therapeutic value and consequently increases success rate with minimum risk of failure.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
This document discusses gene therapy approaches for prostate cancer that have been investigated. It outlines several strategies, including delivering genes to induce cell death or inhibit cell growth, activate the immune system against tumor cells, and target specific gene expression. Clinical trials are evaluating therapies using the herpes simplex virus gene with ganciclovir to activate a prodrug, as well as other approaches to manipulate cell proliferation, apoptosis, angiogenesis, and the immune response. Tissue-specific delivery and regulation of gene expression offer promise for gene therapy in prostate cancer.
Agnostic drugs treat cancers based on the mutations that they display, instead of the tissue type in which they appear.
Pembrolizumab (Keytruda®) is a monoclonal antibody that will be one of the most promising treatments on the market for a range of cancers. By 2024, EvaluatePharma forecasts that Merck's Keytruda will become the world's top-selling drug.
Cytokine Immunotherapy: A Forthcoming Visible Feature in Cancer TherapeuticsSachin K. S. Chauhan
The document discusses cytokine immunotherapy as a promising approach for cancer treatment. It notes that cytokines can stimulate the immune system to fight tumors, but that mono-cytokine therapy has limitations. Combined cytokine therapy or cytokine therapy combined with other treatments may be more effective by creating a specific immune response. The document advocates focusing research on combination therapies to help overcome drawbacks of traditional cancer treatments.
Monoclonal Antibodies As Therapeutic Agents In Oncology Anddrmisbah83
This document discusses monoclonal antibodies as therapeutic agents for cancer and antibody gene therapy. It describes how monoclonal antibodies work to target cancer cells, lists some common monoclonal antibody drugs approved for cancer treatment, and discusses potential side effects. It also introduces the concept of using antibody gene therapy as a new strategy for cancer treatment by delivering antibody genes directly to tumors using vectors like adenovirus or mesenchymal stem cells.
This case report describes an unusual case of pseudo-ankylosis in an 8-year-old child with a history of trauma. Imaging revealed an old fractured right condyle that had been anteriorly displaced and dislocated into the sigmoid notch, where it had fused to the zygomatic arch. Computed tomography with 3D reconstruction clearly showed the displaced condylar fragment. The child underwent surgery to release the ankylotic mass and perform a coronoidectomy to improve mouth opening. Post-operatively, aggressive physiotherapy helped increase the child's maximum interincisal opening. This unique case highlights the importance of accurate imaging and diagnosis for successful treatment of complex facial injuries.
This document provides information about the editors and contributors of the book "Oral and Maxillofacial Surgery for the Clinician". It begins with an introduction by the editors explaining the motivation and scope of the book. It aims to be a comprehensive textbook on oral and maxillofacial surgery for clinicians and trainees. The book has contributions from AOMSI members in India as well as 41 international authors to represent global expertise. It contains 22 sections and 88 chapters covering all aspects of cranio-maxillofacial surgery, along with 68 video demonstrations. The editors thank the contributors and AOMSI for their support in producing this open access textbook.
Here are the key points about suction:
- The objective of suction is to maintain a clear airway by removing secretions like saliva, blood or vomit from the mouth or surgical site.
- It prevents aspiration which can lead to infections. Suction also helps surgeons see clearly during procedures.
- Safety considerations include using proper technique to avoid injury, knowing which patients are at risk of aspiration, monitoring for respiratory distress, and addressing other potential causes of distress beyond just secretions.
This document provides an introduction to mixed dentition space analysis. It discusses that during the mixed dentition period, there may be discrepancies between the space available in the dental arches and the size of the teeth. Accurate mixed dentition space analysis is important for orthodontic diagnosis and treatment planning. The document outlines that mixed dentition typically lasts from ages 6 to 12 years and is when maximum orthodontic problems can develop due to inadequate space for permanent teeth. It also categorizes different methods for mixed dentition space analysis, including those based on regression equations using measurements of erupted permanent teeth and those using radiographs.
This study compared the antifungal efficacy of various endodontic irrigants, with and without the antifungal agent clotrimazole, against Candida albicans in extracted human teeth. Teeth were inoculated with C. albicans and irrigated with sodium hypochlorite, chlorhexidine gluconate, doxycycline hydrochloride, or combinations of these with 1% clotrimazole. Colony forming units were significantly lower for sodium hypochlorite and chlorhexidine alone compared to doxycycline or the control. Adding clotrimazole increased the efficacy of all irrigants, with sodium hypochlorite with clotrimaz
This document discusses the importance of adult immunization and provides guidelines for vaccination against various diseases. It begins by noting that while childhood immunization is well-known, adult immunization is less understood but still important. It then reviews literature on vaccination protocols for adults, including for travel, communicable diseases, hepatitis B, shingles, and more. The document focuses in depth on recommended vaccination for human papillomavirus (HPV), hepatitis, and human immunodeficiency virus (HIV). It provides vaccination schedules, target groups, and notes the need to increase awareness of adult immunization among healthcare professionals and the public.
Mathew P, Kattimani VS, Tiwari RV, Iqbal MS, Tabassum A, Syed KG. New Classification System for Cleft Alveolus: A Computed Tomography-based Appraisal. J Contemp Dent Pract. 2020 Aug 1;21(8):942-948. PubMed PMID: 33568619
Sahu S, Patley A, Kharsan V, Madan RS, Manjula V, Tiwari RVC. Comparative evaluation of efficacy and latency of twin mix vs 2% lignocaine HCL with 1:80000 epinephrine in surgical removal of impacted mandibular third molar. J Family Med Prim Care. 2020 Feb;9(2):904-908. doi: 10.4103/jfmpc.jfmpc_998_19. eCollection 2020 Feb. PubMed PMID: 32318443; PubMed Central PMCID: PMC7113948.
- The document discusses animal models that are being used to test vaccines for COVID-19. It conducted a systematic review of studies published between January and August 2020.
- The review identified 20 relevant studies examining nonhuman primates, mice, hamsters, ferrets, cats and dogs. These animal models show some similar responses to SARS-CoV-2 infection as humans such as respiratory symptoms.
- However, the models do not fully mimic the severe complications seen in human COVID-19 patients such as acute respiratory distress syndrome and coagulopathy. While the models provide useful information, they have limitations in replicating the full disease severity in humans.
This study aimed to evaluate the knowledge and concerns of 124 dental health professionals in southern India regarding COVID-19. A survey was administered to assess understanding of COVID-19 transmission, oral manifestations, appropriate testing and emergency procedures. The results found good knowledge of COVID-19 and precautions, but some lack of awareness regarding appropriate testing and managing contaminated air. While most respondents understood transmission risks and emergency protocols, there was uncertainty around testing patients and using mouthwashes as prevention. This highlights gaps in knowledge that could be addressed with further education for dental professionals on COVID-19 clinical guidelines.
Vohra P, Belkhode V, Nimonkar S, Potdar S, Bhanot R, Izna, Tiwari RVC. Evaluation and diagnostic usefulness of saliva for detection of HIV antibodies: A cross-sectional study. J Family Med Prim Care. 2020 May;9(5):2437-2441. doi: 10.4103/jfmpc.jfmpc_138_20. eCollection 2020 May. PubMed PMID: 32754516; PubMed Central PMCID: PMC7380795
A 34-year-old male presented with pain and pus discharge from a recently extracted tooth. Radiographs showed two distinct radiolucencies - a large cyst in the left mandible and a smaller cyst in the right mandible. Histological examination found the left cyst to be a radicular cyst and the right cyst to be a dentigerous cyst. This presented a diagnostic dilemma as it is uncommon to have multiple cyst types occurring bilaterally in the mandible without an associated syndrome. Careful radiographic and histological analysis was needed to arrive at the accurate diagnosis and appropriate treatment.
Mittal S, Hussain SA, Tiwari RVC, Poovathingal AB, Priya BP, Bhanot R, Tiwari H. Extensive pelvic and abdominal lymphadenopathy with hepatosplenomegaly treated with radiotherapy-A case report. J Family Med Prim Care. 2020 Feb;9(2):1215-1218. doi: 10.4103/jfmpc.jfmpc_1125_19. eCollection 2020 Feb. PubMed PMID: 32318498; PubMed Central PMCID: PMC7113973.
36.Kesharwani P, Hussain SA, Sharma N, Karpathak S, Bhanot R, Kothari S, Tiwari RVC. Massive radicular cyst involving multiple teeth in pediatric mandible- A case report. J Family Med Prim Care. 2020 Feb;9(2):1253-1256. doi: 10.4103/jfmpc.jfmpc_1059_19. eCollection 2020 Feb. PubMed PMID: 32318508; PubMed Central PMCID: PMC7113959.
More from CLOVE Dental OMNI Hospitals Andhra Hospital (20)
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.